Showing results (5041-5050 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|September 2, 2014
Asymptomatic lone atrial fibrillation - how can we detect the arrhythmia?Giuseppe Boriani, Cinzia Valzania, Mauro Biffi, et al.Current Pharmaceutical Design|September 2, 2014
Lone atrial fibrillation - a diagnosis of exclusionAntonio Tello-Montoliu, Diana Hernández-Romero, Marianela Sanchez-Martínez, et al.Current Pharmaceutical Design|September 2, 2014
The heart and brain imaging in lone atrial fibrillation - are we surprised?Eduard Shantsila, Karl Georg Haeusler, Jochen B Fiebach, et al.Current Pharmaceutical Design|September 2, 2014
Lone atrial fibrillation: electrophysiology, risk factors, catheter ablation and other non-pharmacologic treatmentsArun Kanmanthareddy, Martin P Emert, Rhea C Pimentel, et al.Current Pharmaceutical Design|August 28, 2014
Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?Michy P KellyCurrent Pharmaceutical Design|August 28, 2014
Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overviewP R A Heckman, C Wouters, J PrickaertsCurrent Pharmaceutical Design|August 28, 2014
Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfallsRolf T Hansen, Han-Ting ZhangCurrent Pharmaceutical Design|November 23, 2012
Rigorous incorporation of tautomers, ionization species, and different binding modes into ligand-based and receptor-based 3D-QSAR methodsSenthil Natesan, Stefan BalazCurrent Pharmaceutical Design|November 23, 2012
Potential application of network descriptions for understanding conformational changes and protonation states of ABC transportersTamás Hegedűs, Gergely Gyimesi, Merse E Gáspár, et al.Current Pharmaceutical Design|November 23, 2012
Protonation states and conformational ensemble in ligand-based QSAR modelingPier G De BenedettiPageof 1,008